Present Status of Antileishmanial Vaccines
EPrints@IICB
View Archive InfoField | Value | |
Title |
Present Status of Antileishmanial Vaccines
|
|
Creator |
Ghosh, Monidipa
Bandyopadhyay, Santu |
|
Subject |
Infectious Diseases and Immunology
|
|
Description |
The term leishmaniasis refers collectively to various clinical syndromes that are caused by obligate intracellular protozoa of the genus Leishmania. Approximately 350 million people in 8 countries are estimated to be threatened by the disease [1]. The World Health Organization estimated that there are 12 million cases of all forms of leishmaniasis worldwide, with over 500,000 new cases of visceral disease occurring each year [1]. Most of the drugs commonly used to treat different forms of leishmaniasis are toxic and have unacceptable side effects. Moreover, cases of drug resistant leishmaniasis are on the rise. Due to nonexistence of effective vaccine to date, improved immunoprophylactic approaches still remain desirable to combat leishmaniasis. Antileishmanial vaccines developed around the globe are discussed. |
|
Date |
2003
|
|
Type |
Article
PeerReviewed |
|
Format |
application/pdf
|
|
Identifier |
http://www.eprints.iicb.res.in/1629/1/Molecular_and_cellular_biochemistry%2C_2003.pdf
Ghosh, Monidipa and Bandyopadhyay, Santu (2003) Present Status of Antileishmanial Vaccines. Molecular and Cellular Biochemistry, 253. pp. 199-205. |
|
Relation |
http://dx.doi.org/10.1023/A:1026047429604
http://www.eprints.iicb.res.in/1629/ |
|